Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antibody-Drug Conjugate Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment Advanced Refractory Solid Tumors With HER-2 Positive(PRaG3.0)

Next Previous
X
Search
Trial Profile

Antibody-Drug Conjugate Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment Advanced Refractory Solid Tumors With HER-2 Positive(PRaG3.0)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary) ; Granulocyte macrophage colony stimulating factor
  • Indications Advanced breast cancer; Cervical cancer; Gastric cancer; Gynaecological cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms PRaG3.0

    • Most Recent Events

    • 06 Jun 2023 Preliminary results (n=32) assessing efficacy and safety of PRaG3.0 regimen for therapy of HER2-expressing advanced solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2023 According to RemeGen Co., Ltd. media release, data from this trial were presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago.
    • 07 Jun 2022 Status changed from not yet recruiting to recruiting, as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top